Lonza and Vertex Sign Long-Term Supply Agreement for CASGEVY®

Lonza Group AG has announced a long-term commercial supply agreement with Vertex for CASGEVY® (exagamglogene autotemcel), the first CRISPR/Cas9 gene-edited cell therapy. Under this agreement, Lonza will manufacture CASGEVY® for global supply.

CASGEVY® is designed as a one-time treatment for patients with transfusion-dependent beta-thalassemia or sickle cell disease. Lonza’s Geleen (NL) facility, recently approved by the FDA, EMA, and MHRA, will handle the production, with plans to expand to Portsmouth, NH (US) by 2025.

Daniel Palmacci of Lonza expressed excitement about the milestone, while Vertex's Morrey Atkinson highlighted the complexity of manufacturing such an innovative therapy and praised Lonza's partnership. This cooperation aims to ensure CASGEVY®’s availability for patients in need.